Arbutus Biopharma vs. Moderna: LNP Patent Infringement Ruling on COVID-19 Vaccine

Case Overview

In one of the most consequential patent disputes to emerge from the COVID-19 pandemic, Arbutus Biopharma Corporation secured a judgment of infringement against Moderna, Inc. over lipid nanoparticle (LNP) delivery technology embedded in the mRNA-1273 COVID-19 vaccine. This case sits at the intersection of cutting-edge mRNA vaccine technology, pandemic-era government contracting, and foundational LNP delivery patents.

The Parties

Patents at Issue

Seven patents were asserted, all directed to LNP delivery technology that enables mRNA and nucleic acid therapeutics to reach target cells. These patents collectively cover ionizable lipid formulations and LNP compositions critical to delivering mRNA payloads in vivo—the core enabling technology of modern mRNA vaccines and therapeutics.

• • US8492359B2
• • US8058069B2
• • US9504651B2
• • US11141378B2
• • US8822668B2
• • US9364435B2
• • US9404127B2

The Verdict & Legal Analysis

Filed on February 28, 2022, in the District of Delaware, the case ran 1,465 days before closing on March 4, 2026. The case was presided over by Judge Joshua D. Wolson.

Outcome

The court entered a consent judgment of infringement in Arbutus’s favor on Counts 2, 4, 5, and 6 of the Amended Complaint, covering four of the seven asserted patents. Counts 1 and 3 were dismissed with prejudice. The court also entered judgment of no invalidity against Moderna on four corresponding invalidity counterclaims (Declaratory Judgment Counterclaims 8, 10, 11, and 12), based on the asserted patents’ specifications, priority dates, party contentions, and expert opinions.

The §1498 Government Contractor Defense: The Critical Pivot

The most legally distinctive element of this case is the bifurcated resolution of Moderna’s 28 U.S.C. § 1498(a) defense—the federal statute that bars patent infringement claims when patented inventions are used or manufactured by or for the United States government.

The court’s analysis divided the COVID-19 vaccine doses into two categories:

• Doses distributed to the general public under the C-100 Contract: Not protected under §1498—infringement judgment entered for Arbutus.
• 6,244,340 doses administered directly to U.S. Government employees: Protected under §1498—judgment entered for Moderna.

This bifurcation is legally significant. It confirms that §1498 immunity is not a blanket shield for government-contracted pandemic products distributed broadly to civilians. The court’s nuanced reading—tying immunity specifically to direct government employee administration—provides a narrowing interpretation that patent holders in government-adjacent markets will cite aggressively in future litigation.

The court also rejected Arbutus’s fraud-in-the-inducement theory regarding the C-100 Contract’s validity, entering judgment for Moderna on that theory.

Validity Analysis

The no-invalidity judgment on four patent claims—entered based on specifications, priority dates, and competing expert positions—reinforces the durability of Arbutus’s LNP portfolio claims when subjected to adversarial validity challenge. No specific prior art was found to invalidate the asserted claims under the record developed by the parties.

Strategic Takeaways

For patent attorneys, the §1498 sovereign immunity analysis offers critical strategic lessons. For IP professionals in the biopharma space, the outcome confirms the enforceability of Arbutus’s core LNP portfolio. For R&D teams developing nucleic acid therapeutics, this ruling signals that freedom-to-operate (FTO) clearance around LNP delivery patents remains non-negotiable.